Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call

  Pharmacyclics Announces Date of Financial Results for Three and Six Months
                 Ended December 31, 2012 and Conference Call

PR Newswire

SUNNYVALE, Calif., Feb. 7, 2013

SUNNYVALE, Calif., Feb. 7, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the
"Company") (Nasdaq: PCYC) today announced that it will report financial
results and recent developments for its three and six months ended December
31, 2012 after the NASDAQ Market closes on Thursday, February 14, 2013. The
Company will conduct a conference call and audio webcast at 4:30 p.m ET on the
same day. As previously announced, the Company changed its fiscal year end
from June 30 to December 31, effective December 31, 2012. As a result, the six
months ended December 31, 2012 represent a transition period, with the next
fiscal year covering the period from January 1, 2013 through December 31,
2013.

Conference call and webcast details:

Date: February 14, 2013
Time: 4:30 PM ET
Listen via Internet: http://ir.pharmacyclics.com/events.cfm
Toll-free: (877)-407-0778
International: (201)-689-8565

Replay Number (Toll Free): (877)-660-6853
Replay Number (International): (201)-612-7415
Conference ID #: 409002

A webcast replay will be available on the Pharmacyclics website for 30 days.

About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on
developing and commercializing innovative small-molecule drugs for the
treatment of cancer and immune mediated diseases. Our mission and goal is to
build a viable biopharmaceutical company that designs, develops and
commercializes novel therapies intended to improve quality of life, increase
duration of life and resolve serious unmet medical healthcare needs; and to
identify promising product candidates based on scientific development and
administrational expertise, develop our products in a rapid, cost-efficient
manner and pursue commercialization and/or development partners when and where
appropriate.

Presently, Pharmacyclics has three product candidates in clinical development
and several research molecules in lead optimization. We are committed to high
standards of ethics, scientific rigor, and operational efficiency as we move
each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ
under the symbol PCYC. To learn more about how Pharmacyclics advances science
to improve human healthcare visit us at http://www.pharmacyclics.com.

SOURCE PHARMACYCLICS/ ACCOUNTS PAYABLE

Website: http://www.pharmacyclics.com
Contact: Joshua T. Brumm, Executive Vice President, Finance, +1-408-215-3311,
or Ramses Erdtmann, Vice President of Investor Relations, +1-408-215-3325
 
Press spacebar to pause and continue. Press esc to stop.